Session Speaker: "Healthy, Wealthy & Wise: The Social & Economic Potential of a Vibrant Human Therapeutics Industry in NZ"

Dr Joshua Funder joined GBS in 2004 with experience in biotechnology management, business strategy and the international pharmaceutical industry. Before joining GBS Joshua worked in corporate strategy and development at Infinity Pharmaceuticals in Boston and the Boston Consulting Group in San Francisco. In addition he worked with the Clinton Foundation HIV/AIDS Initiative to successfully negotiate reduced prices for anti-retrovirals and initiate pharmaceutical supplies across eastern and southern Africa. Joshua served as interim CEO of Proacta Inc following GBS investment and is on the board of directors of GBS portfolio companies OPAL Inc, Peplin Inc, Spinifex Pharmaceuticals, Pathway Therapeutics and Nuon Therapeutics.

Joshua earned his Bachelor of Science (Honours) and Bachelor of Laws (Honours) degrees at Melbourne University and his Master of Laws degree at the London School of Economics. He holds a D.Phil in intellectual property for biotechnology from Oxford University where he studied as a Rhodes Scholar.